Business Wire

Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally

5.1.2021 16:00:00 EET | Business Wire | Press release

Share

MyHeritage, the leading global platform for discovering your past and empowering your future, announced today that it is sponsoring a racing team in the 2021 Dakar Rally — the elite off-road endurance competition currently taking place in Saudi Arabia. The MyHeritage team comprises driver Danny Pearl, a veteran of off-road racing, and navigator Charly Gotlib, who has participated in the Dakar Rally more than 30 times over the years, and has received an honorary distinction of Dakar Legend from the race organizers. The team is managed by Omer Pearl, Danny’s son. In recent years, Omer has managed the Pearl Racing Team in different competitions around the world. The team is named the MyHeritage Team and is competing in the Dakar’s Lightweight Vehicle category.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005542/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally (Photo: Business Wire)

As the international market leader for exploring family history and finding relatives, MyHeritage develops innovative search and matching technologies and has a global database of historical records to help millions of people connect to their family history. Sponsoring a team led by a father-son duo is par for the course for MyHeritage. The company has a long history of partnering with top athletes, sports teams, and cultural figures to reveal their family history, forge connections with their relatives, and underscore the importance of knowing one’s roots.

Danny and Omer Pearl founded the Pearl Racing Team out of their passion for motorsports. The team has competed for many years in the SSV category, racing in numerous international competitions.

The Dakar Rally is considered the toughest and most grueling off-road competition in the world. This is the second year the competition is being held in Saudi Arabia, following its relocation from South America, where it was held for the last decade. The race spans more than 7,000 kilometers and 12 days over the challenging and beautiful Saudi terrain. This year’s race departed from Jeddah and will traverse the entire Arabian desert in a circular course. Each day the team will navigate under the most extreme conditions, using a Road Book produced by the rally organizer.

“As leaders in the field of exploring and discovering family history, we are thrilled to support a team that includes a father and son who are competing in one of the world’s most difficult competitions,” said Gilad Japhet, Founder and CEO of MyHeritage. “Particularly during these challenging times, we appreciate the significance of supporting family members coming together in bold and creative ways, working as a team to achieve the impossible. Just like the Dakar, family history can be an enjoyable and adventurous journey.”

“It is with great pride and excitement that we enter this legendary race,” said Omer Pearl. “We believe that determination and perseverance yield results, and our family bond is one of the driving forces behind our success. We hope that our efforts will inspire more families to team up and work together to pursue their dreams.”

The Dakar Rally is taking place between January 3–15, 2021.

About MyHeritage

MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. Launched in 2016, MyHeritage DNA has become one of the world’s largest consumer DNA databases, with more than 4.6 million customers. Since 2020, MyHeritage is home to the world’s best technologies for enhancing and colorizing historical photos. MyHeritage is the most popular DNA test and family history service in Europe. www.myheritage.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye